Parkinson's Disease Drug Development Since 1999: A Story of Repurposing and Relative Success.

ABSTRACT:

Background

A global overview of drug development programs in Parkinson's disease over the last few decades is lacking, while such programs are challenging given the multifaceted and heterogeneous nature of the disease.

Objective

To indirectly assess drug development programs in Parkinson's disease, exploring some factors associated with compound attrition at different trial phases.

Methods

We assessed all Parkinson's disease trials in the WHO trials portal, from inception (1999) to September 2019. Independent authors selected trials and extracted data. The success rate was the number of compounds that progressed to the next drug development phase divided by the number of compounds in that phase.

Results

Overall, 357 trials (studying 152 compounds) fulfilled our

SUBMITTER: Boucherie DM 

PROVIDER: S-EPMC8150606 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature